Pharma Contract Manufacturing Exchange 2021 will be hosting a brand new format including a virtual exchange limited to senior Pharmaceutical and Biopharmaceutical attendees responsible for managing their external partner networks, to ensure high-level focused conversations.
Join this engaging digital exchange of knowledge and relationship-building, in the absence of face-to-face meetings, to share ideas, discuss best practices and stimulate innovation during these times of uncertainty.
David O’Connell – Director of Scientific Affairs at PCI Pharma Services will be speaking about The Critical Aspects to Consider when choosing the right CDMO for HPAPI Development and Manufacturing.
Topics covered will include the complexities involved in the safe handling of potent molecules and increasing regulatory requirements, it is imperative to choose the right partner for the successful development and manufacturing, and ultimate commercialization of such molecules. Identifying a partner with the relevant capabilities, expertise and experience to collaborate with through this journey is a critical decision point for any company looking to outsource.
Attendees will learn about:
- The key considerations in the development and manufacturing of highly potent products
- The complexities involved with the processing of highly potent molecules, including OEL assessment, safe processing and cleaning procedures
- Regulatory guidelines and best practice for the safe handling of highly potent molecules
- The key considerations when identifying and evaluating a potential CDMO partner for HPAPI development and manufacturing
PCI are sponsoring this event, and Wayne James and Gareth Coleman will also be online to discuss Pharmaceutical challenges.
For more information or to register for this event, please see the event website
Event: Pharma Contract Manufacturing Exchange 2021
Date: 23 - 24 March, 2021 | Online - All timings in GMT
Where: Virtual Forum